MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Akerna Corp. Revenue 2011-2026 | KERN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Akerna Corp.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.5 M | 21.9 M | 10.5 M | 20.7 M | 12.6 M | 10.9 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.9 M | 10.5 M | 16.2 M |
Quarterly Revenue Akerna Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.2 M | 1.38 M | 1.56 M | - | 11.6 M | 5.52 M | 7.49 M | - | 5.48 M | 5.28 M | 2.6 M | - | 3.06 M | 3.49 M | 4.25 M | - | 5.14 M | 4.91 M | 4.01 M | - | 3.71 M | 3 M | 3.71 M | 3.31 M | 3.19 M | 6.5 M | 3.19 M | 2.57 M | 2.3 M | - | 2.32 M | 2.86 M | 2.67 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64.2 M | 1.38 M | 6.27 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Accolade
ACCD
|
170 M | - | 0.29 % | $ 206 M |  USA |
 |
Change Healthcare
CHNG
|
3.09 B | - | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B | USA |
 |
Health Catalyst
HCAT
|
311 M | $ 1.1 | -9.5 % | $ 76.9 M | USA |
 |
American Well Corporation
AMWL
|
249 M | $ 5.76 | -0.52 % | $ 92.4 M | USA |
 |
Computer Programs and Systems
CPSI
|
339 M | - | 4.4 % | $ 133 M | USA |
 |
HealthStream
HSTM
|
292 M | $ 20.97 | -0.76 % | $ 637 M | USA |
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
NextGen Healthcare
NXGN
|
557 M | - | - | $ 1.6 B | USA |
 |
Omnicell
OMCL
|
1.11 B | $ 34.46 | 0.44 % | $ 1.59 B | USA |
 |
1Life Healthcare
ONEM
|
623 M | - | - | $ 3.37 B | USA |
 |
OptimizeRx Corporation
OPRX
|
71.5 M | $ 6.78 | 5.44 % | $ 116 M | USA |
 |
HealthEquity
HQY
|
1.31 B | $ 82.1 | 0.56 % | $ 7.07 B | USA |
 |
Phreesia
PHR
|
356 M | $ 11.28 | -4.41 % | $ 615 M | USA |
 |
Premier
PINC
|
263 M | - | - | $ 2.33 B | USA |
 |
Evolent Health
EVH
|
382 M | $ 2.25 | -9.64 % | $ 211 M | USA |
 |
MTBC
MTBC
|
120 M | - | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
792 M | $ 2.04 | -1.92 % | $ 787 M | USA |
 |
Schrödinger
SDGR
|
256 M | $ 11.57 | -2.53 % | $ 850 M | USA |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.5 B | - | -10.39 % | $ 886 M | USA |
 |
Teladoc Health
TDOC
|
2.53 B | $ 5.42 | -1.09 % | $ 955 M | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
Zhongchao
ZCMD
|
16.3 M | $ 1.81 | -4.23 % | $ 9.42 M |  China |
 |
10x Genomics
TXG
|
619 M | $ 19.81 | 3.5 % | $ 2.32 B | USA |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
2.99 M | $ 0.13 | -4.16 % | $ 190 K | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
Progyny
PGNY
|
298 M | $ 18.05 | 0.22 % | $ 1.55 B | USA |
 |
So-Young International
SY
|
-1.52 M | $ 2.91 | - | $ 231 M | China |
 |
Veeva Systems
VEEV
|
3.2 B | $ 179.11 | -3.3 % | $ 29.3 B | USA |